Optimer (NASDAQ: OPTR) is developing novel carbohydrate chemistry to attack antibiotics-resistant bacteria.  Currently, the company has 2 proprietary antibiotics under late stage of clinical trials.  The company went public in February 2007. The company was acquired by Cubist Pharmaceuticals in August 2013. Cubist was acquired by Merck in 2014.